Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study

@article{Yao2008VirologicSA,
  title={Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-na{\"i}ve Chinese patients with chronic hepatitis B: a randomized, multicenter study},
  author={Guang Yao and Chengwei Chen and Weilun Lu and Hongkai Ren and Deming Tan and Yuming Wang and Daozheng Xu and Jessica Liu and Dong Ying Xu and Cyril Llamoso},
  journal={Hepatology International},
  year={2008},
  volume={2},
  pages={486 - 493}
}
PURPOSE Entecavir demonstrated superior virologic and biochemical benefits over lamivudine at 48 weeks in nucleoside-naïve Chinese patients with chronic hepatitis B (CHB). We evaluated the effect of continued entecavir and lamivudine treatment in patients who continued treatment in year 2 and the off-treatment durability of patients who achieved a protocol-defined consolidated response at week 48. METHODS Chinese adults (n = 519) with CHB were randomized to a minimum of 52 weeks of treatment… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Clinical utility of entecavir for chronic hepatitis B in Chinese patients

Drug design, development and therapy • 2013
View 19 Excerpts
Highly Influenced

Control of hepatitis B in China: prevention and treatment.

Expert review of anti-infective therapy • 2011

Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.

Liver international : official journal of the International Association for the Study of the Liver • 2010
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 27 references

BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis

TT Chang, RG Gish, +3 authors YC Chao
B. N Engl J Med • 2006
View 16 Excerpts
Highly Influenced

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

The New England journal of medicine • 2006
View 14 Excerpts
Highly Influenced

Adefovir Dipivoxil 438 Study Group. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis

SJ Hadziyannis, NC Tassopoulos, +3 authors M Rizzetto
B. N Engl J Med • 2008

Taiwan Community-Based Cancer Screening Project Group

HI Yang, SN Lu, +3 authors LY Wang
Hepatol Int • 2008

Bristol-Myers Squibb Research and Development. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients [abstract 781

RJ Colonno, RE Rose, +3 authors D Xu
J Hepatol • 2007
View 2 Excerpts

Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(?) antiviral-naive adults: 48 wk results (E.A.R.L.Y. study) [abstract 49

N Leung, CY Peng, +3 authors L Jeffers
J Hepatol 2007;46(Suppl • 2007
View 1 Excerpt

Four year assessment of ETV resistance in nucleoside - naive and lamivudine refractory patients [ abstract 781 ]

RJ Colonno, RE Rose, +3 authors D Xu
J Hepatol • 2007

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2006